Liquidia/LQDA

$13.95

-9%
-
1D1W1MYTD1YMAX

About Liquidia

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

Ticker

LQDA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Roger Jeffs

Employees

136

Headquarters

Morrisville, United States

Liquidia Metrics

BasicAdvanced
$1.17B
Market cap
-
P/E ratio
-$1.21
EPS
0.19
Beta
-
Dividend rate
$1.17B
0.1927
$16.99
$5.71
906.7K
4.846
91.942
97.697
-26.14%
-63.43%
-114.01%
-71.31%
66.646
22.246
29.167
9.75%
-72.79%
187.02%

What the Analysts think about Liquidia

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
71.04% upside
High $32.00
Low $3.00
$13.95
Current price
$23.86
Average price target

Liquidia Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-608.88% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$4.5M
25%
Net income
$-27.4M
74.52%
Profit margin
-608.88%
39.62%

Liquidia Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 78.61%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.18
-$0.36
-$0.24
-$0.42
-
Expected
-$0.16
-$0.16
-$0.21
-$0.24
-$0.32
Surprise
10.92%
120.47%
12.07%
78.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Liquidia stock?

Liquidia (LQDA) has a market cap of $1.17B as of April 13, 2024.

What is the P/E ratio for Liquidia stock?

The price to earnings (P/E) ratio for Liquidia (LQDA) stock is 0 as of April 13, 2024.

Does Liquidia stock pay dividends?

No, Liquidia (LQDA) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Liquidia dividend payment date?

Liquidia (LQDA) stock does not pay dividends to its shareholders.

What is the beta indicator for Liquidia?

Liquidia (LQDA) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Liquidia stock price target?

The target price for Liquidia (LQDA) stock is $23.86, which is 71.04% above the current price of $13.95. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Liquidia stock

Buy or sell Liquidia stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing